CD274 and neoplasm: There are several biomarkers to identify patients who may benefit from immunotherapies, including the PD-L1 status of tumor cells (and immune cells in the tumor microenvironment), tumor mutation burden, invasion of CD8-positive cells, and the absence of suppressive immune cells.